Recently, Elpiscience was officially recognized as a National High-Tech Enterprise and was also named to the first tier of the 2026 China Top 100 Pharmaceutical Innovation Seed Enterprises. These two prestigious recognitions represent endorsements from both China's national innovation policy framework and industry authority evaluations, underscoring the company's innovation capabilities and growth potential. Together, they validate the company's comprehensive strengths in technological innovation, R&D system development, and research translation, further highlighting its value and potential as an emerging innovative biopharmaceutical company.

Elpiscience has officially been certified as a National High-Tech Enterprise and received the official certificate. This accreditation is a key qualification in China's scientific and technological innovation sector, based on a comprehensive evaluation of multiple dimensions, including core proprietary intellectual property, commercialization of scientific and technological achievements, R&D organization and management, growth potential, and talent structure. This recognition signifies that Elpiscience has received authoritative national validation of its independent innovation capabilities, R&D excellence, and sustainable development potential, and will provide strong support for the company's future innovation and development.

Meanwhile, leading pharmaceutical industry media HEALTHCARE EXECUTIVE recently released the 2026 “China Top 100 Pharmaceutical Innovation Seed Enterprises” list. In recognition of its solid R&D foundation, sustained innovation capabilities, and outstanding research achievements, Elpiscience was named to the first tier. The ranking focuses on emerging innovators in China's pharmaceutical industry and evaluates companies across three key dimensions: innovation foundation, innovation process, and innovation outcomes. The assessment integrates competitive intelligence, clinical trial, and patent data from Clarivate Cortellis to systematically evaluate corporate innovation capabilities. The selected companies are regarded as a vital emerging force driving China's transition from a major pharmaceutical producer to a pharmaceutical powerhouse.

Committed to original innovation in immunology, Elpiscience focuses on oncology and autoimmune diseases, and is dedicated to developing next-generation immunotherapies with global competitiveness. The company continues to advance research on cutting-edge targets and pathways while building a differentiated pipeline. It has established an integrated antibody discovery and development platform spanning the entire R&D lifecycle from drug discovery, translational medicine to clinical development, while also assembling a high-caliber R&D team with both international vision and industry experience, creating a comprehensive and efficient R&D system.

The company's proprietary BiME® platform is among the first myeloid cell engager (MCE) technology platforms developed globally, providing a foundation for the discovery and development of next-generation immunotherapies. The company currently has four clinical-stage pipeline assets and multiple preclinical programs targeting diseases with significant unmet medical needs across oncology and autoimmune indications, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), biliary tract cancer (BTC), colorectal cancer (CRC), desmoid tumors (DT), and inflammatory bowel disease (IBD). Concurrently, the company continues to strengthen its global intellectual property portfolio to reinforce protection of its proprietary technologies.

Since the beginning of 2026, Elpiscience's innovative R&D has continued to achieve important milestones, entering a new phase of value realization. The first-in-class CD39/TGF-β bispecific antibody ES014, the globally leading hexavalent OX40 agonist ES102, and the next-generation anti-angiogenic VEGF/DLL4 bispecific antibody ES104, have each achieved significant clinical progress in difficult-to-treat cancers, including DT, HNSCC, and BTC, with clinical validation continuing to accelerate. Meanwhile, multiple autoimmune pipeline programs have efficiently advanced, achieving key objectives.

Looking ahead, Elpiscience will continue to drive innovation through original innovation and differentiated R&D, strengthen core technology capabilities, advance its global development, and accelerate the translation of innovative outcomes into clinical and industrial value, with the goal of becoming a leading global innovative biopharmaceutical company.